Impact of IFNα2b upon pSTAT3 and the MEK/ERK MAPK Pathway in Melanoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2008, v. 57, n. 9, p. 1315, doi. 10.1007/s00262-008-0466-9
- By:
- Publication type:
- Article
Works matching IS 03407004 AND DT 2008 AND VI 57 AND IP 9
Results: 15
1
2
CD54 is a surrogate marker of antigen presenting cell activation.
- Published in:
- Cancer Immunology, Immunotherapy, 2008, v. 57, n. 9, p. 1381, doi. 10.1007/s00262-008-0474-9
- By:
- Publication type:
- Article
3
TARC and RANTES enhance antitumor immunity induced by the GM-CSF-transduced tumor vaccine in a mouse tumor model.
- Published in:
- Cancer Immunology, Immunotherapy, 2008, v. 57, n. 9, p. 1399, doi. 10.1007/s00262-008-0476-7
- By:
- Publication type:
- Article
4
Experimental manipulations of afferent immune responses influence efferent immune responses to brain tumors.
- Published in:
- Cancer Immunology, Immunotherapy, 2008, v. 57, n. 9, p. 1323, doi. 10.1007/s00262-008-0467-8
- By:
- Publication type:
- Article
5
The role of extracellular matrix metalloproteinase inducer protein in prostate cancer progression.
- Published in:
- Cancer Immunology, Immunotherapy, 2008, v. 57, n. 9, p. 1367, doi. 10.1007/s00262-008-0473-x
- By:
- Publication type:
- Article
6
Second international conference on cancer vaccines/adjuvants/delivery for the next decade (CVADD): Heidelberg, Germany, 10–12 October 2007.
- Published in:
- Cancer Immunology, Immunotherapy, 2008, v. 57, n. 9, p. 1421, doi. 10.1007/s00262-008-0470-0
- By:
- Publication type:
- Article
7
Investigation of the mechanisms of tissue factor-mediated evasion of tumour cells from cellular cytotoxicity.
- Published in:
- Cancer Immunology, Immunotherapy, 2008, v. 57, n. 9, p. 1347, doi. 10.1007/s00262-008-0469-6
- By:
- Publication type:
- Article
8
Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers.
- Published in:
- Cancer Immunology, Immunotherapy, 2008, v. 57, n. 9, p. 1413, doi. 10.1007/s00262-008-0477-6
- By:
- Publication type:
- Article
9
Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain.
- Published in:
- Cancer Immunology, Immunotherapy, 2008, v. 57, n. 9, p. 1279, doi. 10.1007/s00262-008-0461-1
- By:
- Publication type:
- Article
10
Toll-like receptors expressed in tumor cells: targets for therapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2008, v. 57, n. 9, p. 1271, doi. 10.1007/s00262-008-0459-8
- By:
- Publication type:
- Article
11
Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses.
- Published in:
- Cancer Immunology, Immunotherapy, 2008, v. 57, n. 9, p. 1291, doi. 10.1007/s00262-008-0462-0
- By:
- Publication type:
- Article
12
Fas-mediated T cell deletion potentiates tumor antigen-specific tolerance in a mouse model of prostate cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2008, v. 57, n. 9, p. 1357, doi. 10.1007/s00262-008-0471-z
- By:
- Publication type:
- Article
13
Development of a Listeria monocytogenes based vaccine against prostate cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2008, v. 57, n. 9, p. 1301, doi. 10.1007/s00262-008-0463-z
- By:
- Publication type:
- Article
14
Danger signals and nonself entity of tumor antigen are both required for eliciting effective immune responses against HER-2/neu positive mammary carcinoma: implications for vaccine design.
- Published in:
- Cancer Immunology, Immunotherapy, 2008, v. 57, n. 9, p. 1391, doi. 10.1007/s00262-008-0475-8
- By:
- Publication type:
- Article
15
High frequency of immature dendritic cells and altered in situ production of interleukin-4 and tumor necrosis factor-α in lung cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2008, v. 57, n. 9, p. 1335, doi. 10.1007/s00262-008-0468-7
- By:
- Publication type:
- Article